Los Angeles Capital Management
COGT icon

Los Angeles Capital Management’s Cogent Biosciences COGT Stock Holding History

Los Angeles Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
29,086
+28,743
+8,380% +$1.06M ﹤0.01% 645
2025
Q4 		$5.56K Buy
+343
New +$9.64K ﹤0.01% 2257

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Los Angeles Capital Management's COGT Position: Q1 2026 in Review

Los Angeles Capital Management increased its Cogent Biosciences (COGT) stake by 8,380% in Q1 2026, buying an estimated $1.06M and bringing the position to 29,086 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Los Angeles Capital Management first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Los Angeles Capital Management held 29,086 shares of Cogent Biosciences worth $1.12M as of Q1 2026.
  • Los Angeles Capital Management bought 28,743 Cogent Biosciences shares in Q1 2026, an estimated $1.06M.
  • Cogent Biosciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #645 holding.
  • Los Angeles Capital Management first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.